Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer

被引：0
|
作者：
Silvia Cantara
Eugenio Bertelli
Rossella Occhini
Marì Regoli
Lucia Brilli
Furio Pacini
Maria Grazia Castagna
Paolo Toti
机构：
[1] University of Siena,Department of Medical, Surgical and Neurological Sciences
[2] University of Siena,Department of Molecular and Developmental Medicine
[3] Arezzo Hospital,Unit of Pathology
[4] University of Siena,undefined
来源：
Endocrine | 2019年 / 64卷
关键词：
PD-L1; PD-1; Anaplastic thyroid cancer; Immunotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：122 / 129
页数：7
相关论文
共 50 条
  • [41] Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Incorvaia, Lorena
    Fanale, Daniele
    Badalamenti, Giuseppe
    Barraco, Nadia
    Bono, Marco
    Corsini, Lidia Rita
    Galvano, Antonio
    Gristina, Valerio
    Listi, Angela
    Vieni, Salvatore
    Gori, Stefania
    Bazan, Viviana
    Russo, Antonio
    ADVANCES IN THERAPY, 2019, 36 (10) : 2600 - 2617
  • [42] Targeting Programmed Cell Death-1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
    Constantinidou, Anastasia
    Alifieris, Constantinos
    Trafalis, Dimitrios T.
    PHARMACOLOGY & THERAPEUTICS, 2019, 194 : 84 - 106
  • [43] Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy
    Razaghi, Ali
    Durand-Dubief, Mickael
    Brusselaers, Nele
    Bjornstedt, Mikael
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [44] Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
    Gatalica, Zoran
    Snyder, Carrie
    Maney, Todd
    Ghazalpour, Anatole
    Holterman, Daniel A.
    Xiao, Nianqing
    Overberg, Peggy
    Rose, Inga
    Basu, Gargi D.
    Vranic, Semir
    Lynch, Henry T.
    Von Hoff, Daniel D.
    Hamid, Omid
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (12) : 2965 - 2970
  • [45] Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors
    Zhang, Lin
    Qiu, Miaozhen
    Jin, Ying
    Ji, Jiao
    Li, Baoxia
    Wang, Xueping
    Yan, Shumei
    Xu, Ruihua
    Yang, Dajun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (09): : 11084 - 11091
  • [46] Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
    Wu, Mengling
    Huang, Qianrui
    Xie, Yao
    Wu, Xuyi
    Ma, Hongbo
    Zhang, Yiwen
    Xia, Yong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [47] Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas
    Spurny, Christian
    Kailayangiri, Sareetha
    Jamitzky, Silke
    Altvater, Bianca
    Wardelmann, Eva
    Dirksen, Uta
    Hardes, Jendrik
    Hartmann, Wolfgang
    Rossig, Claudia
    PEDIATRIC BLOOD & CANCER, 2018, 65 (01)
  • [48] In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC)
    Wang, Yubo
    Zhou, Yuanyuan
    Cao, Sheng
    Sun, Yue
    Dong, Zhiqiang
    Li, Chen
    Wang, Haoran
    Yao, Yuhong
    Yu, Haiyan
    Song, Xiangyi
    Li, Ming
    Wang, Jiefu
    Wei, Mingming
    Yang, Guang
    Yang, Cheng
    BIOORGANIC CHEMISTRY, 2021, 111
  • [49] Programmed-cell death ligand 1 (PD-L1) expression in equine sarcoids and squamous cell carcinoma
    Pimenta, Jose
    Prada, Justina
    Pires, Isabel
    Cotovio, Mario
    OPEN VETERINARY JOURNAL, 2024, 14 (06) : 1476 - 1482
  • [50] Angiogenesis, programmed death ligand 1 (PD-L1) and immune microenvironment association in laryngeal carcinoma
    Franz, Leonardo
    Alessandrini, Lara
    Calvanese, Leonardo
    Crosetta, Giulia
    Frigo, Anna Chiara
    Marioni, Gino
    PATHOLOGY, 2021, 53 (07) : 844 - 851
12345